PIH37 Cost Effectiveness Analysis Of The Use Of Human Fibrinogen (Clottafact®) In Masive Post-Partum Hemorragea In Mexico  by Contreras, I. et al.
A160  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  
screening may reduce the annual number of stillbirths by up to 2,900, neonatal 
deaths by up to 1,100, the annual incidence of congenital syphilis by up to 1,450 and 
avert up to 130,000 DALYs at an incremental annual direct medical cost of US$ 5.9 
million. The three relatively high prevalence countries of Brazil, Colombia and Haiti, 
account for over half of the total DALYs that could potentially be averted, whereas 
Chile and Cuba have already adopted universal screening. ConClusions: Use of 
ICS tests for antenatal syphilis screening is highly cost-effective in low and middle 
income countries in Latin America. Antenatal programs should either expand access 
or maintain full access to syphilis screening using the ICS test.
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objeCtives: Coffee (Coffea arabica) contains over 1,000 distinct molecular compounds 
and is one of the most widely consumed beverages worldwide. Epidemiologic stud-
ies have shown an inverse relationship between coffee consumption and all-cause 
mortality. This analysis aims to assess the cost-effectiveness of coffee from the 
perspective of the US consumer and payer. Methods: A cohort life-table analysis 
was developed to model life-years (LYs) of US coffee consumers vs non-consumers 
over a lifetime horizon. Age- and gender-specific mortality rates were used to model 
survival outcomes. Relative risks of death by average coffee intake (cups/day) were 
obtained from a recent large, prospective US cohort study. Costs per cup were esti-
mated for home preparation and obtained from a national sample of low- and high-
cost vendors. Incremental analyses were conducted by cost, sex, and level of daily 
coffee consumption. Deterministic (DSA) and probabilistic (PSA) sensitivity analy-
ses were conducted. The model was validated by comparing life expectancy results 
to a model utilizing relative risks of cancer and chronic diseases based on coffee 
consumption. Results: Coffee increased undiscounted LYs in 1, 2-3, 4-5, and 6+ 
cup/day male (0.72, 1.23, 1.48, and 1.22) and female (0.53, 1.42, 1.77, 1.65) consumers, 
respectively, versus non-consumers. ICERs per discounted LY gained were $5,460, 
$11,326, $24,254 for males and $5,885, $8,910, $20,145 for females, respectively, for 
1, 2-3, and 4-5 cups/day consumption of home-prepared coffee; 6+ cups/day was 
strictly dominated. Consumption of 4-5 cups per day purchased from high-cost ven-
dors was not cost-effective, with ICERs > $50,000/LY-gained. DSA showed that coffee 
effectiveness in preventing death and coffee acquisition cost had the largest impact 
on ICERs. ConClusions: In this analysis, coffee consumption was associated with 
increased LYs and was shown to be potentially cost-effective, especially if home-
prepared or purchased from low-cost vendors. Given the observational nature of the 
study data, further research is warranted to validate these findings.
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objeCtives: Maternal Death (MD) is a health public issue in Mexico, the MD Ratio 
(MDR) is 43.2 deaths/100,000 newborns, the Post-Partum Hemorragea (PPH) repre-
sents the second cause of MD (23%), with a higher impact in mexican provinces with 
poor or limited blood products access. The purpose of this study was to estimate 
from the health service provider perspective, the cost-effectiveness in the use of 
Human Fibrinogen (HF) (Clottafact®) in the hematologic treatment of masive PPH 
during limited access of boold products (access after 20 minutes). Methods: A 
decition tree was created to estimate the survival probabilities and costs of PPH 
under a limited blood product access scenario, the use of HF or the use of recom-
binant Factor VII alfa (Factor rVIIa). The effectiveness was obtained from literature. 
The costs were estimated throughout an expert consensus and were expressed in US 
Dollars (exchange rate 1USD/13.0 MXN). The CER and ICER were estimated per saved 
live and a probabilistic sensibility analysis was performed. Results: The average 
cost per treated patient with limited access to blood products was 12,350 USD, with 
HF was $13,182 USD wheras with Factor rVIIa it was $14,526 USD. The survival rate 
was 0.59, 0.98 and 0.93 respectively. The cost per saved life with limited treatment 
was $21,238 USD, with HF was $13,410 and with Factor rVIIa it was $15,552 USD. The 
acceptability curve shows that the use of HF is cost-effective in 65% to 85% of the 
cases with a $3,000 USD willingness to pay limit. ConClusions: Human Fibrinogen 
represents the best treatment alternative for the PPH in Mexican provinces with 
poor access to blood products and it would significantly reduce the MDR in Mexico.
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objeCtives: The objective of the study was to assess the cost-effectiveness of 
hysteroscopic tubal sterilization (HTS) for permanent birth control, compared with 
laparoscopic tubal sterilization (LTS). Methods: Cost effectiveness was addressed 
through an economic evaluation using a decision analytic model that compared 
the health benefits and resource expenditures associated with three alternative 
protocols: Calgary HTS protocol, Saskatchewan HTS protocol, and LTS. The analysis 
adopted a payer perspective and considered direct medical service costs to the 
Alberta health system, including costs of physician, hospital and confirmative 
diagnosis. The time horizon for the analysis considered costs from initial surgery 
to follow-up diagnosis up to 6 months post-surgery. Clinical and epidemiological 
data came from a review of literature and expert opinions. Cost data for LTS were 
primarily obtained from provincial administrative databases. Results: Both the 
be cost-effective compared to the most prominent comparators in management of 
infertility in The Netherlands.
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objeCtives: This study aimed to evaluate the cost-effectiveness of LNG-IUS 13.5mg, 
a low-dose hormonal intrauterine contraceptive system for use up to 3 years, rela-
tive to the most commonly used oral contraceptive (OC) in Canada from a societal 
perspective. Methods: A state-transition model was developed to assess the 
cost-effectiveness of LNG-IUS 13.5mg over 3 years in a cohort of 1,000 women of 
reproductive age (15-44 years). The comparator was a generic version of the 100 
mcg levonorgestrel and 20 mcg ethinyl estradiol OC. The model consisted of three 
mutually exclusive health states: initial contraceptive method, unplanned preg-
nancy (UP) due to contraceptive failure and subsequent contraceptive method, taken 
up following UP or due to discontinuation of the initial method. The subsequent 
contraceptive method was represented by a basket of market-weighted contracep-
tives. Contraceptive failure and discontinuation rates were taken from published 
literature, resource use was estimated from product monographs and unit costs 
were taken from standard Ontario and Quebec cost databases. Analysis from the 
societal perspective allowed the model to incorporate economic costs associated 
with missed work. The key model output was cost per UP avoided. Probabilistic 
sensitivity analyses (PSA) were performed. Results: LNG-IUS 13.5mg dominated 
the OC method, resulting in fewer UP (8 vs. 180) and lower total costs ($665,224 vs. 
$1,102,456), representing a savings of $437,232 over 3 years. Overall savings resulted 
from fewer UP and avoided costs associated with the uptake of the subsequent con-
traceptive method. PSA results indicated a high probability of dominance as all itera-
tions showed LNG-IUS 13.5mg to be more effective and less costly. ConClusions: 
LNG-IUS 13.5mg is an effective contraceptive option that generates savings com-
pared to a generic OC.
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objeCtives: Postpartum hemorrhage (PPH) is a leading cause of maternal death. 
Although the strong evidence showing the efficacy of oxytocin in preventing PPH, its 
use remains suboptimal. The Uniject injection system prefilled with oxytocin (OiU) 
has the potential advantage, due to its ease of use, to increase oxytocin coverage rates 
(OCR). This study objective is to evaluate the cost-effectiveness of OiU in Latin America 
(LAC). Methods: We built an epidemiological model to estimate the impact of replac-
ing oxytocin in ampoules with OiU on the incidence of PPH, quality-adjusted life 
years (QALYs) and costs from a health care perspective. A systematic search for data 
on epidemiology and cost studies was undertaken. A consensus panel among LAC 
experts was performed to quantify the expected increase in OCR as a consequence 
of making OiU available. Deterministic and probabilistic sensitivity analyses were 
performed. Results: In the threshold analysis the minimum required increment in 
the OCR to make OiU a cost-effective strategy ranged from 1.3% in Suriname to 16.2% 
in Haiti. In more than 60% of the countries, the required increment was below 5%. OiU 
could prevent more than 40,000 PPH episodes annually in LAC. In 27% of the countries 
OiU showed to be cost saving. In the remaining 21 countries OiU was associated with 
a net cost increment ($ 0.005 to $0.780 2013 US dollars per delivery). OiU strategy 
ranged from being dominant to having an ICER of $ 9,454 per QALY gained. In the great 
majority of countries these ICERs were below one GDP per capita. ConClusions: 
OiU was cost-saving or very cost-effective in almost all countries. Even if countries 
can achieve only small increases in OCR by incorporating OiU, this strategy could be 
considered an efficient use of resources. These results showed to be robust in the 
sensitivity analysis under a wide range of assumptions and scenarios.
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objeCtives: Untreated syphilis in pregnancy is associated with adverse clinical 
outcomes to the infant. In Latin America, roughly three out of every ten women 
are not tested for syphilis during pregnancy. The objective of this analysis was 
to evaluate the cost-effectiveness, budget impact, and potential reduction in 
adverse pregnancy outcomes of antenatal syphilis screening using the recently 
introduced point of care immunochromatographic strip test across 20 countries in 
Latin America. Methods: A previously published cost-effectiveness model was 
adapted to reflect the perspectives of the respective national health care systems. 
Clinical outcomes of infants born to syphilis-infected mothers on the endpoints 
of stillbirth, neonatal death and congenital syphilis were obtained from published 
sources. Treatment was assumed to consist of three injections of benzathine penicil-
lin. Country-specific inputs included the antenatal prevalence of syphilis; annual 
number of live births; proportion of women with at least one antenatal care visit; 
per capita gross national income and estimated hourly nurse wages. Results: In 
all 20 Latin American countries, syphilis screening is highly cost-effective with an 
weighted average cost/DALY averted of US$110 (range: US$10-US$308). Universal 
